DOI:
10.1055/s-00000031
Klinische Monatsblätter für Augenheilkunde
LinksClose Window
References
Martinez-Garcia M, Banerji U, Albanell J. et al.
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Clin Cancer Res 2012;
18: 4806-4819
doi:10.1158/1078-0432.CCR-12-0742
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.